For exploratory purposes, patients whose tumor contained a loss-of-function (LOF) mutation in at least one of the 18 HRR genes including BRCA1/2 were considered as HRRm (Supplementary Fig. S1). The gene discussed is BRCA1; the disease is neoplasm.